AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$7.42 USD
-0.13 (-1.72%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $7.40 -0.02 (-0.27%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.42 USD
-0.13 (-1.72%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $7.40 -0.02 (-0.27%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum B VGM
Zacks News
Intuitive Surgical (ISRG) Earnings Miss, Revenues Beat in Q4
by Zacks Equity Research
Solid show by flagship da Vinci system drives Intuitive Surgical's (ISRG) Q4 results.
Accuray's (ARAY) Q2 Loss Narrows, Radixact Demand Shoots Up
by Zacks Equity Research
Demand for flagship Radixact & CyberKnife platforms aids Accuray's (ARAY) fiscal Q2 results.
CONMED (CNMD) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
CONMED's (CNMD) Q4 results get a boost from solid segmental performances.
Here's Why Investors Should Hold AngioDynamics (ANGO) Now
by Zacks Equity Research
AngioDynamics' (ANGO) flagship NanoKnife System is currently witnessing robust demand.
AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife
by Zacks Equity Research
AngioDynamics (ANGO) sees a solid fiscal second quarter; gains from strong segmental contributions.
AngioDynamics (ANGO) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 4.76% and 2.93%, respectively, for the quarter ended November 2018. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Hold AngioDynamics Stock Now
by Zacks Equity Research
AngioDynamics' (ANGO) gains from solid prospects in the NanoKnife platform. However, sluggishness in the Venous Insufficiency business is a headwind.
AngioDynamics (ANGO) Down 6.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Q1 Earnings Miss, '19 Sales View Up
by Zacks Equity Research
AngioDynamics (ANGO) sees soft segmental performances in Q1; international sales surge.
AngioDynamics (ANGO) Lags Q1 Earnings Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -11.11% and 2.36%, respectively, for the quarter ended August 2018. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) Q1 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for AngioDynamics (ANGO) in Q1 Earnings?
by Zacks Equity Research
Expanding product portfolio, international market expansion and cost-saving initiatives to drive AngioDynamics (ANGO) in Q1.
Here's Why You Should Hold AngioDynamics' (ANGO) Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) to benefit from a solid product portfolio. However, the company???s core Peripheral Vascular business has been sluggish.
AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.
New Strong Sell Stocks for September 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for August 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for August 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.
Why Is AngioDynamics (ANGO) Up 5.02% Since Its Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Align, AngioDynamics and Caterpillar highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Align, AngioDynamics and Caterpillar highlighted as Zacks Bull and Bear of the Day
Bear of the Day: AngioDynamics (ANGO)
by Kevin Cook
Small cap force in non-surgical alternatives for peripheral vascular disease hits a growth/valuation peak
AngioDynamics (ANGO) Q4 Performance Dull, Competition Rife
by Zacks Equity Research
AngioDynamics' (ANGO) fourth-quarter performance dull; stiff competition a serious concern.
AngioDynamics (ANGO) Misses Q4 Earnings & Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) misses Q4 earnings and revenue estimates; international sales high.
AngioDynamics (ANGO) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -4.76% and -0.75%, respectively, for the quarter ended May 2018. Do the numbers hold clues to what lies ahead for the stock?